Key data
Open—
From 52W high—
Volume—
Market cap—
P/E (TTM)—
P/S (TTM)—
Div yield—
Key data
Open
—
From 52W high
—
Volume
—
Market cap
—
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
—
P/E (TTM)
—
RSI (14)
—
MomentumView details →
1D Return
—
YTD Return
—
SummaryUpdated Jun 1, 2026
Genmab A/S (NASDAQ:GMAB) is a Danish biotechnology company founded in 1999 and headquartered in Copenhagen, Denmark. The company went public in 2009 and has established itself as a leading developer of innovative antibody therapeutics for cancer treatment. Genmab has evolved from a research-focused biotech startup into a commercially successful company with multiple approved products and a robust pipeline of experimental treatments. The company operates through strategic partnerships with major pharmaceutical companies while also developing and commercializing its own proprietary medicines.
Latest newsMore news →
GENMAB A/S shares rose during a breakout week, adding about $10 billion in market value, amid stellar cancer-drug data.8h agoGENMAB A/S shares surged to a record high.2d agoGENMAB A/S announced positive topline results from the Phase 3 LiGeR-HN1 trial, reporting that petosemtamab plus pembrolizumab met both primary endpoints and reduced the risk of death by 50% versus pembrolizumab alone in first-line PD-L1-positive recurrent or metastatic head and neck squamous cell carcinoma.2d ago